The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
94 | 92 | 92 | 97 |
Growth
|
49 | 43 | 7 | 27 |
Safety
|
29 | 30 | 31 | 35 |
Sentiment
|
63 | 40 | 68 | 51 |
|
72 | 51 | 39 | 55 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
7 | 9 | 10 | 34 |
Opinions Change
|
80 | 12 | 48 | 64 |
Pro Holdings
|
n/a | 88 | 87 | 40 |
Market Pulse
|
54 | 79 | 78 | 68 |
Sentiment
|
63 | 40 | 68 | 51 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
94 | 92 | 92 | 97 |
Growth
|
49 | 43 | 7 | 27 |
|
29 | 30 | 31 | 35 |
Combined
|
63 | 58 | 29 | 52 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
91 | 83 | 91 | 96 |
Price vs. Earnings (P/E)
|
51 | 43 | 37 | 40 |
Price vs. Book (P/B)
|
29 | 23 | 19 | 35 |
Dividend Yield
|
98 | 98 | 98 | 98 |
Value
|
94 | 92 | 92 | 97 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
6 | 6 | 25 | 11 |
Profit Growth
|
98 | 100 | 31 | 47 |
Capital Growth
|
28 | 17 | 26 | 48 |
Stock Returns
|
51 | 61 | 37 | 73 |
Growth
|
49 | 43 | 7 | 27 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
13 | 16 | 24 | 34 |
Refinancing
|
27 | 27 | 25 | 25 |
Liquidity
|
75 | 75 | 76 | 66 |
|
29 | 30 | 31 | 35 |
Discover high‑ranked alternatives to Bristol-Myers Squibb and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.